---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-278688"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2024-12-13T23:59:59+00:00"
generated_at: "2026-05-29T03:22:10.255247+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics board members Altman and Poukalov resign; board rebalanced

## Summary
- Michael Altman and Konstantin Poukalov resigned from Lyra Therapeutics Board effective December 12, 2024.
- Maria Palasis, Ph.D. moved from Class III to Class I director to rebalance board classes; term extended to 2027.
- Board now consists of two Class I, two Class II, and two Class III directors.

## SEC filing metadata
- accession: 0001193125-24-278688
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2024-12-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000119312524278688/0001193125-24-278688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000119312524278688/d888261d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-278688
- JSON: https://secwatch.observer/filing/0001193125-24-278688.json
- Plain text: https://secwatch.observer/filing/0001193125-24-278688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.